Detalhe da pesquisa
1.
CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/ß-catenin axis.
Mol Cancer
; 20(1): 153, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34852843
2.
Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma.
Nat Commun
; 15(1): 5183, 2024 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38890370
3.
Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy.
Front Med
; 17(4): 699-713, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37060525
4.
Concurrent remission of lymphoma and Sjögren's disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report.
Front Immunol
; 14: 1298815, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38173731
5.
Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells.
Sci Rep
; 12(1): 12506, 2022 07 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35869100
6.
A novel lncRNA TCLlnc1 promotes peripheral T cell lymphoma progression through acting as a modular scaffold of HNRNPD and YBX1 complexes.
Cell Death Dis
; 12(4): 321, 2021 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33767152
7.
CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial.
Genome Med
; 12(1): 41, 2020 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32349779
8.
Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
Clin Cancer Res
; 25(23): 6995-7003, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31444250
9.
Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways.
J Exp Clin Cancer Res
; 37(1): 63, 2018 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29554968
10.
JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide.
Sci Rep
; 7(1): 7433, 2017 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28785100
11.
Clinical efficacy and tumour microenvironment influence of decitabine plus R-CHOP in patients with newly diagnosed diffuse large B-Cell lymphoma: Phase 1/2 and biomarker study.
Clin Transl Med
; 11(12): e584, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34923760
12.
[Clinical and prognostic analysis of 21 cases of primary breast lymphoma].
Zhonghua Xue Ye Xue Za Zhi
; 36(4): 277-81, 2015 Apr.
Artigo
em Zh
| MEDLINE | ID: mdl-25916285
13.
MicroRNA181a Is Overexpressed in T-Cell Leukemia/Lymphoma and Related to Chemoresistance.
Biomed Res Int
; 2015: 197241, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26436088
14.
Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.
Nat Genet
; 47(9): 1061-6, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26192917